Azole Derivatives as Cannabinoid CB1 Receptor Antagonists
申请人:LEE Jinhwa
公开号:US20080262066A1
公开(公告)日:2008-10-23
A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB
1
receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.